Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
Authors
Yasunobu Ishizuka
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Yasunobu Ishizuka , Yukiya Narita , Tomoki Sakakida , Munehiro Wakabayashi , Hiroyuki Kodama , Kazunori Honda , Toshiki Masuishi , Hiroya Taniguchi , Shigenori Kadowaki , Masashi Ando , Masahiro Tajika , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 268)
DOI
10.1200/JCO.2024.42.3_suppl.268
Abstract #
268
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
First Author: Mohammad Jad Moussa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.
First Author: Mai Utsumi